Search
Cetrimonium
go.drugbank.com/drugs/DB01718ApprovedInvestigationalCetrimonium is a quaternary ammonium cation whose salts are used as antiseptics.
Synonyms: N,N,N-Trimethyl-1-hexadecanaminiumMixtures: QUIRUCIDAL NF, NW BENZALKONIUM AND CETRIMIDE CREAMFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn.
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada.
Tirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800]
Segesterone acetate
go.drugbank.com/drugs/DB14583ApprovedSegesterone acetate is a steroidal progestin or synthetic progesterone and a 19-norprogesterone derivative with no CH3 group radical in position 6 [A37048].
RUS 3108
go.drugbank.com/drugs/DB05911ExperimentalThe drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Masitinib
go.drugbank.com/drugs/DB11526InvestigationalVet approvedIt has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Synonyms: 4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDEN2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide
go.drugbank.com/drugs/DB03456ExperimentalN2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide is a solid. This compound belongs to the n-acyl-alpha amino acids and derivatives.
Synonyms: N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamideTrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118] … [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries